Gilead Sciences Inc (GILD) Financials
Key financial figures for Gilead Sciences Inc (Q2 2026).
Gilead's Q2 2026 revenue grew 10% to $7.8B on HIV/Trodelvy/Livdelzi strength, but a $11.2B acquired IPR&D charge from the Arcellx, Tubulis, and Ouro Medicines deals drove a GAAP diluted loss of $(8.45) and a non-GAAP diluted loss of $(6.75) per share. Total Q2 2026 revenue rose 10% year-over-year to $7.80 billion, beating the $7.6 billion prior guide, driven by HIV, Trodelvy, and Livdelzi. GAAP diluted loss per share was $(8.45) versus $1.56 a year ago; non-GAAP diluted loss per share was $(6.75) versus $2.01 a year ago, both driven by a $(9.08)-per-share impact from acquired IPR&D and related tax expenses tied to the Arcellx, Tubulis, and Ouro Medicines acquisitions (net of the Lakefront collaboration). On the outlook: Raised FY2026 product sales guidance to $30.1 billion to $30.4 billion (from $30.0 to $30.4 billion) and product sales excluding Veklury to $29.8 billion to $30.1 billion (from $29.4 to $29.8 billion); lowered Veklury guidance to approximately $300 million (from approximately $600 million); GAAP diluted loss per share guidance widened to $(3.75) to $(3.40) and non-GAAP diluted loss per share to $(0.65) to $(0.30), both reflecting the approximately $9.08 per share impact of the $11.1 billion in acquired IPR&D charges from the Arcellx, Tubulis, and Ouro Medicines transactions. Figures are for Q2 2026, as Gilead Sciences, Inc. reported them.
- Revenue
- $7.8B
- Net Income
- -$10.5B
- EPS
- $-8.45
- Total Assets
- $49.4B
- Operating Cash Flow
- $3.6B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $7.8B | -$10.5B | -$8.45 | -133.21% | |
| Q1 FY2026 | $7.0B | $2.0B | $1.61 | 37.16% | $2.4B |
| Q4 FY2025 | $7.9B | $2.2B | $1.74 | 37.71% | $3.1B |
| Q3 FY2025 | $7.8B | $3.1B | $2.43 | 42.82% | $4.0B |
| Q2 FY2025 | $7.1B | $2.0B | $1.56 | 34.94% | $720M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $29.4B | $8.5B | $6.78 | 39.74% | $9.5B |
| FY2024 | $28.8B | $480M | $0.38 | 5.78% | $10.3B |
| FY2023 | $27.1B | $5.7B | $4.50 | 28.05% | $7.4B |
Frequently asked questions
What was Gilead Sciences, Inc.'s revenue last quarter?
Gilead Sciences, Inc. reported revenue of $7.80 billion for Q2 FY2026, up 10.2% from the same period a year earlier.
Is Gilead Sciences, Inc. profitable?
Not in its most recent reported period. Gilead Sciences, Inc. reported a net loss of $10.50 billion for Q2 FY2026, a net margin of -134.51% on revenue.
How has Gilead Sciences, Inc.'s margin trended?
Operating margin was -133.21% in Q2 FY2026, compared with 34.94% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How many quarters of Gilead Sciences, Inc. financials does SentiSense hold?
SentiSense holds up to forty quarters and twenty fiscal years of income statement, balance sheet and cash flow history for GILD. The 5 most recent quarters are summarised above.
Full income statement, balance sheet and cash flow for Gilead Sciences Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.